Zymeworks Common Valuation
| ZYME Stock | USD 12.72 0.21 1.62% |
At this time, the company appears to be overvalued. Zymeworks Common Stock maintains a prevalent Real Value of $10.83 per share. The last-minute price of the company is $12.72. Our model calculates the value of Zymeworks Common Stock from examining the company fundamentals such as Return On Asset of -0.15, current valuation of 677.75 M, and Profit Margin of (1.61) % as well as analyzing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Zymeworks Common's price fluctuation is somewhat reliable at this time. Calculation of the real value of Zymeworks Common Stock is based on 3 months time horizon. Increasing Zymeworks Common's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Zymeworks stock is determined by what a typical buyer is willing to pay for full or partial control of Zymeworks Common Stock. Since Zymeworks Common is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Zymeworks Stock. However, Zymeworks Common's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 12.72 | Real 10.83 | Hype 12.72 | Naive 13.89 |
The real value of Zymeworks Stock, also known as its intrinsic value, is the underlying worth of Zymeworks Common Stock Company, which is reflected in its stock price. It is based on Zymeworks Common's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Zymeworks Common's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Zymeworks Common Stock helps investors to forecast how Zymeworks stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Zymeworks Common more accurately as focusing exclusively on Zymeworks Common's fundamentals will not take into account other important factors: Zymeworks Common Total Value Analysis
Zymeworks Common Stock is at this time expected to have valuation of 677.75 M with market capitalization of 899.63 M, debt of 18.48 B, and cash on hands of 241.83 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Zymeworks Common fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
677.75 M | 899.63 M | 18.48 B | 241.83 M |
Zymeworks Common Investor Information
About 100.0% of the company outstanding shares are owned by institutional investors. The book value of Zymeworks Common was at this time reported as 4.91. The company recorded a loss per share of 1.62. Zymeworks Common Stock had not issued any dividends in recent years. Based on the analysis of Zymeworks Common's profitability, liquidity, and operating efficiency, Zymeworks Common Stock is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April.Zymeworks Common Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Zymeworks Common has an asset utilization ratio of 0.0165 percent. This indicates that the Company is making $1.65E-4 for each dollar of assets. An increasing asset utilization means that Zymeworks Common Stock is more efficient with each dollar of assets it utilizes for everyday operations.Zymeworks Common Ownership Allocation
Zymeworks Common Stock retains a total of 69.58 Million outstanding shares. The majority of Zymeworks Common outstanding shares are owned by institutional investors. These institutions are usually referred to as non-private investors looking to purchase positions in Zymeworks Common Stock to benefit from reduced commissions. Consequently, other corporate entities are subject to a different set of regulations than regular investors in Zymeworks Common Stock. Please pay attention to any change in the institutional holdings of Zymeworks Common Stock as this could imply that something significant has changed or is about to change at the company. Also note that almost sixty-eight thousand eight hundred eighty-one invesors are currently shorting Zymeworks Common expressing very little confidence in its future performance.Zymeworks Common Profitability Analysis
The company reported the previous year's revenue of 76.3 M. Net Loss for the year was (122.69 B) with loss before overhead, payroll, taxes, and interest of (60.2 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Zymeworks Common's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Zymeworks Common and how it compares across the competition.
About Zymeworks Common Valuation
The stock valuation mechanism determines Zymeworks Common's current worth on a weekly basis. Our valuation model uses a comparative analysis of Zymeworks Common. We calculate exposure to Zymeworks Common's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Zymeworks Common's related companies.Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada. Zymeworks operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. It employs 284 people.
Zymeworks Common Growth Indicators
Investing in growth stocks can be very risky. If the company such as Zymeworks Common does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 75.9 M |
Complementary Tools for Zymeworks Stock analysis
When running Zymeworks Common's price analysis, check to measure Zymeworks Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zymeworks Common is operating at the current time. Most of Zymeworks Common's value examination focuses on studying past and present price action to predict the probability of Zymeworks Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zymeworks Common's price. Additionally, you may evaluate how the addition of Zymeworks Common to your portfolios can decrease your overall portfolio volatility.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |